#Ibuprofen Market Growth
Explore tagged Tumblr posts
Text
https://carbonfacesocial.org/blogs/46687/Ibuprofen-API-Market-Size-Share-and-Forecast-2031
The Ibuprofen API Market was US$ 7.4 billion in 2022, and is projected to expand at a CAGR of 3.5% over the forecast period of 2023-2031.
0 notes
Text
Opioid Market Size, Share, Trends And Industry Outlook Report, 2030
Opioids Market Growth & Trends
The global opioid market size is expected to reach USD 25.3 billion by 2030, registering a CAGR of 1.4% during the forecast period, according to a new report by Grand View Research, Inc. Supportive regulatory policies aid manufacturers to introduce products that may contribute to the market growth. For instance, in June 2021, the U.S. FDA approved nalmefene hydrochloride injection developed by Purdue Pharma L.P.Nalmefene injectable is an opioid antagonist designed to reverse opioid overdose. The expected approval of a product is anticipated to drive the growth.
Moreover, in June 2021, morphine sulfate tablets and morphine sulfate oral solution were approved by FDA for the management of severe pain in pediatric and adult patients for whom other treatment options were less. Thus, approval of new opioid and their launch is also expected to drive the growth.
Growing use of the opioids for the management of post-operative pain, caused due to the surgeries, is expected to drive the market growth. According to the Canadian Centre on Substance Use and Addiction, in 2020, approximately 11.8% of all the population used opioid analgesics for the management of symptoms. Tramadol and codeine are frequently dispensed for the postoperative opioid prescription in surgeries within the region.
Emergence of non-addictive alternative products to opioids for the pain-management leads to decline in the growth of opioid market. According to American Society of Anesthesiologists, there are several non-opioid medicines that are available over the counter steroids and NSAIDs such as aspirin, ibuprofen, and acetaminophen among others. Furthermore, wide availability and low cost associated with these drugs contribute to increase in demand for such products during the forecast period. For instance, aspirin cost USD 10 for a pack of 30 tablets.
In addition, in February 2022, the U.S. FDA has undertaken an initiative to encourage the development of non-addictive analgesics alternatives to opioids under its HHS overdose prevention strategy for the management of acute and chronic pain. The regulatory agency issued recommendation to pharmaceutical companies to develop non-opioid analgesic products. Such initiatives may restrain the overall growth of the opioids market.
Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/opioids-market
Opioids Market Report Highlights
By product, ER/long acting opioids segment held the largest market share in 2022 due to the increasing approval and launch of the novel ER/ long-acting opioids. For instance, in June 2021, the U.S. FDA accepted a review application for a new drug application for buprenorphine (Brixadi) for the pain management. Buprenorphine is an extended release long-acting opioid drug
By application, pain relief segment dominated the opioids market in 2022 and is expected to witness significant market growth owing to increasing prevalence of the patients with chronic pain. According to the Canadian Institute for Health Information and Canadian Pain Task Force report of 2021, 1 in every 5 adults in Canada suffers from chronic pain
By route of administration, injectable segment dominated the opioids market in 2022. This dominance can be attributed to wide availability of products used for the treatment of chronic pain and increased procedures requiring anesthesia
By distribution channel, retail pharmacy dominated the opioids market in 2022. The availability of retail pharmacies with high dispensing rate of opioid driving segment growth
Asia pacific is expected to be the fastest growing region during the forecast period. The growth of the region can be attributed to increasing geriatric population which are susceptible to the chronic pain.
Opioids Market Segmentation
Grand View Research has segmented the global opioid market based on product, application, route of administration, distribution channel, and region:
Opioids Product Outlook (Revenue, USD Million, 2018 - 2030)
IR/Short Acting Opioids
ER/Long-Acting Opioids
Opioids Application Outlook (Revenue, USD Million, 2018 - 2030)
Pain relief
Anesthesia
Cough suppression
Diarrhea suppression
De-addiction
Opioids Route of administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral
Injectable
Others
Opioids Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital pharmacy
Retail Pharmacy
Others
Opioids Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
List of Key Players in the Opioids Market
Purdue Pharma L.P.
Johnson & Johnson Services, Inc.
Hikma Pharmaceuticals PLC
Pfizer, Inc.
AbbVie Inc.
Sanofi
Sun Pharmaceutical Industries Ltd
Grünenthal
Browse Full Report: https://www.grandviewresearch.com/industry-analysis/opioids-market
0 notes
Text
Sciatica Treatment Market: Trends, Growth, and Insights (2023 - 2030)
The global Sciatica Market, a condition characterized by pain radiating along the sciatic nerve, is a prevalent and often debilitating issue affecting millions worldwide. It can arise from a variety of causes, such as herniated discs, spinal stenosis, or injury to the lower back. As awareness about the condition grows and the demand for effective treatments rises, the sciatica treatment market has witnessed significant growth. In 2023, the market size is valued at $12.18 billion, with projections indicating it will grow to $13.42 billion by 2024 and reach $24.04 billion by 2030, driven by a strong compound annual growth rate (CAGR) of 10.20%. This blog explores the dynamics of the sciatica treatment market, key treatment types, market players, regional analysis, and the key trends shaping the industry.
Understanding Sciatica and Its Impact
Sciatica refers to pain that travels along the sciatic nerve, typically affecting one side of the body. The sciatic nerve is the longest and largest nerve in the body, running from the lower back through the hips and buttocks, and down each leg. Sciatica is often a symptom of an underlying condition, such as a herniated disc, spinal stenosis, or piriformis syndrome. The pain can range from mild to severe and can impact daily activities, work, and overall quality of life.
The condition affects millions of people globally, with a significant prevalence in adults aged 30 to 50. As the population ages, the demand for effective treatment solutions continues to rise, propelling growth in the sciatica treatment market.
Types of Sciatica Treatments
The treatment for sciatica can be broadly categorized into two major types: medication and surgical treatments. The choice of treatment depends on the severity and underlying cause of the condition, as well as the patient’s overall health and response to other treatments.
Medication: Medications are typically the first line of treatment for sciatica. They help manage pain, reduce inflammation, and alleviate muscle spasms. Common medications used in sciatica treatment include:
Pain Relievers: Over-the-counter (OTC) pain relievers like ibuprofen or acetaminophen are often recommended for mild to moderate pain.
Muscle Relaxants: These are prescribed for muscle spasms that often accompany sciatica.
Anti-inflammatory Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce swelling and alleviate pain.
Corticosteroid Injections: In more severe cases, corticosteroid injections are administered to reduce inflammation around the nerve root.
Opioids: These may be prescribed for short-term pain management in severe cases, although their use is limited due to the risk of addiction.
Surgical Treatment: Surgery is considered when non-invasive treatments like medication and physical therapy fail to alleviate the symptoms. Surgical options may include:
Microdiscectomy: A minimally invasive procedure where a portion of the herniated disc is removed to relieve pressure on the sciatic nerve.
Laminectomy: A surgical procedure where a part of the vertebra is removed to create more space around the spinal cord and nerve roots.
Spinal Fusion: In some cases, spinal fusion may be necessary to stabilize the spine if there is significant damage to the vertebrae or discs.
Artificial Disc Replacement: This involves replacing a damaged disc with an artificial one to restore proper function and reduce pain.
The increasing prevalence of sciatica, particularly in aging populations, and the ongoing advancements in surgical technologies are key drivers of the growing demand for both medication and surgical treatments.
Key Market Segments by Application
Sciatica treatment is offered across different healthcare settings. The key segments by application include:
Hospitals: Hospitals play a central role in the treatment of sciatica, especially for patients requiring surgical intervention or complex diagnostic procedures. Hospitals offer comprehensive care with access to specialists, advanced imaging, and surgical treatment options. The demand for sciatica treatment in hospitals is expected to continue growing, particularly due to the rise in the aging population and the increasing number of surgeries performed for spine-related disorders.
Clinics: Clinics, including outpatient and specialty centers, provide primary care and non-invasive treatments for sciatica. These include physical therapy, pain management, chiropractic treatments, and injections. Clinics are increasingly becoming popular due to their cost-effectiveness and the ability to treat patients on an outpatient basis. Many patients with mild to moderate sciatica prefer seeking treatment at clinics to avoid the cost and complexity of hospital care.
Others: Other settings, such as rehabilitation centers and pain management centers, also contribute to the treatment of sciatica. These facilities may offer specialized services like physical therapy, acupuncture, and alternative treatments, often in combination with traditional medications.
Market Growth and Trends
The sciatica treatment market has witnessed steady growth, driven by the increasing prevalence of spinal disorders and sciatica, particularly in aging populations. The market size in 2023 stands at $12.18 billion and is expected to grow to $13.42 billion in 2024, reaching $24.04 billion by 2030, with a CAGR of 10.20%. Several key trends are driving this growth:
Rising Prevalence of Sciatica: As the global population ages, the incidence of conditions that lead to sciatica, such as herniated discs and degenerative spine disorders, has increased. Chronic back pain and sciatica are more common in older adults, leading to an increase in the demand for treatments.
Advancements in Treatment Options: Innovations in medical technology have improved the effectiveness and safety of sciatica treatments. Minimally invasive surgical procedures, like microdiscectomy and laminectomy, are gaining popularity due to their shorter recovery times and reduced risks compared to traditional open surgeries. Additionally, newer medications, including more effective anti-inflammatory drugs and biologics, are improving patient outcomes.
Increased Awareness and Access to Healthcare: Increased awareness about sciatica and its treatments, coupled with improvements in healthcare access, is driving the growth of the market. As patients become more educated about their treatment options, they are more likely to seek medical attention earlier, leading to faster diagnoses and more timely interventions.
Non-Surgical Treatment Options: With a growing preference for non-invasive treatments, there is increasing demand for physical therapy, chiropractic care, and alternative therapies. These treatments, often used in conjunction with medications, are helping to manage symptoms without the need for surgery.
Telemedicine and Remote Monitoring: The rise of telemedicine and remote patient monitoring is also impacting the sciatica treatment market. Through telemedicine platforms, patients can consult with healthcare providers, manage pain medications, and access rehabilitation programs without needing to visit a clinic or hospital.
Key Market Players
Several major players are shaping the sciatica treatment market by providing innovative solutions for pain management, surgery, and rehabilitation. Key players include:
Pfizer
Johnson & Johnson
Bayer AG
Novartis AG
Sanofi
AstraZeneca
Teva Pharmaceutical
Omron Healthcare
Omega Laser Systems Ltd
Abbott
Endo International plc.
GSK plc.
Bristol Myers Squibb
Amneal Pharmaceuticals LLC
Sorrento Therapeutics
These companies offer a wide range of products, including pain relief medications, surgical tools, and rehabilitation equipment. Their ongoing investment in R&D ensures that they remain competitive in an increasingly crowded market.
Regional Insights
The sciatica treatment market spans across several regions, each exhibiting different growth dynamics. Here’s a closer look at the major regions:
North America: North America holds the largest share of the sciatica treatment market, driven by advanced healthcare infrastructure, a high prevalence of chronic back pain, and the presence of leading pharmaceutical companies. The U.S. is the primary contributor to market growth in this region.
Europe: Europe is another significant market for sciatica treatment, with countries like Germany, the U.K., and France leading in terms of demand. The aging population and the increasing adoption of minimally invasive treatments are key factors driving market growth in Europe.
Asia Pacific: The Asia Pacific region is expected to experience the highest growth in the coming years, driven by improving healthcare infrastructure, increasing awareness of sciatica, and rising healthcare spending in countries like China, India, and Japan.
Latin America: Latin America’s sciatica treatment market is gradually expanding due to increased access to healthcare and rising awareness of spinal health. Brazil and Mexico are the major markets in this region.
Middle East & Africa: The Middle East & Africa region is witnessing gradual growth, with countries like Saudi Arabia and South Africa showing increasing demand for advanced sciatica treatments as healthcare infrastructure improves.
Conclusion: The Future of Sciatica Treatment
The sciatica treatment market is poised for robust growth, driven by technological advancements, an aging population, and increasing demand for both surgical and non-surgical treatment options. With a projected market size of $24.04 billion by 2030, the industry is witnessing substantial investment in new drugs, surgical techniques, and rehabilitation solutions. As the global awareness of sciatica continues to rise, healthcare providers and pharmaceutical companies will continue to innovate to meet the needs of patients, ensuring improved outcomes and better management of the condition. The future of the sciatica treatment market is bright, offering a wealth of opportunities for companies and healthcare professionals alike.
Browse More:
Attacking Rajnath Singh's Congress, alleging that Robert Badra has grabbed farmers' land
0 notes
Text
Over The Counter Pain Medication market will grow at highest pace owing to rising geriatric population
The over the counter pain medication market consists of non-prescription drugs used to relieve pain such as headaches, muscle pains, backaches, toothaches, colds, menstrual cramps and arthritis. These drugs provide temporary relief from pain and include analgesics like paracetamol and non-steroidal anti-inflammatory drugs such as ibuprofen and aspirin. Non-prescription pain medications are widely available as tablets, capsules and liquids in retail pharmacies and online stores, providing convenience to consumers. With growing aging population suffering from arthritis and other joint pains, the demand for these medications is increasing rapidly.
The Global Over The Counter Pain Medication Market is estimated to be valued at US$ 27.12 Bn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Over The Counter Pain Medication market include Johnson & Johnson, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Reckitt Benckiser Group plc, Novartis AG, Perrigo Company plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited. The dominance of these key players is attributed to their diverse product portfolio and strong global distribution network.
Over The Counter Pain Medication Market Demand rapidly owing to increasing incidences of headache, joint pains and menstrual problems across major countries. Self-medication has become popular as consumers frequently purchase these drugs for quick relief from minor pains without doctor's prescription.
Technological advancements are leading to development of innovative drug delivery systems for over the counter pain medications such as fast-dissolving oral thin films and gels providing pain relief more quickly. Development of combination drugs offering relief from multiple symptoms with a single drug is another key trend observed in this market. Market Trends Sustained release formulations are gaining popularity in the over the counter pain medication market. These ensure drugs remain effective for longer duration, releasing medicine slowly into the body. For example, Advil has introduced extended release gels providing all-day relief from pain.
Combination drugs offering relief from pain as well as symptoms like cold, cough and fever are witnessing strong demand. Consumers prefer single drugs treating multiple conditions. Manufacturers are developing combination pills accordingly to increase sales.
Market Opportunities The rising geriatric population suffering from arthritis and joint pains worldwide presents significant growth opportunities. Around 100 million US adults suffer from arthritis currently and the number is projected to rise to 130 million by 2060.
Online pharmacies are emerging as an important sales channel for over the counter pain medications. Expanding e-commerce and increasing preference of consumers to shop online from the convenience of their homes will drive future revenues in this distribution segment.
Impact of COVID-19 on Over The Counter Pain Medication Market Size And Trends The COVID-19 pandemic has immensely impacted the growth of the over the counter pain medication market globally. During the initial phase of the pandemic, there was a sharp surge in demand for pain relieving drugs like paracetamol, ibuprofen etc. as people stocked up medicines fearing potential shortages. This led to a significant spike in sales revenues for OTC pain medication manufacturers in 2020. However, as the pandemic prolonged, lockdowns imposed worldwide disrupted manufacturing and supply chain operations. Strict movement restrictions made it difficult for companies to transport raw materials and finished drugs. The declining disposable incomes and job losses during the economic downturn also reduced people's spending power which hindered the market growth post-2020.
To overcome resource constraints, companies focused on streamlining production and prioritizing essential medicines. They established alternative sourcing routes and enhanced inventory levels. Digitization of processes helped maintain business continuity. As restrictions eased in 2021-22, market saw a steady recovery backed by mass vaccination drives. Demand revived in retail channels and e-commerce platforms. However, hovering price pressures due to high production costs remain a key challenge. In the coming years, companies need to optimize costs, expand into virtual care solutions and tap opportunities in pain relief for Covid-19 associated symptoms to sustain growth in the post pandemic environment. Geographical Regions with Highest Over The Counter Pain Medication Market Value North America has been the largest regional market for over the counter pain medication, accounting for around 40% of global value due to high healthcare spending and self-medication trend. Within North America, the US commands the major share owing to large population size and presence of major manufacturers. Europe holds the second position while Asia Pacific is fastest growing region supported by expanding medical industries, rising health awareness and large patient pool in China and India. Fastest Growing Region in Over The Counter Pain Medication Market Asia Pacific region is poised to witness the fastest growth in the over the counter pain medication market during the forecast period. Factors such as rising middle class disposable incomes, increased spending on healthcare, growing geriatric population susceptible to joint disorders and innovations by local pharmaceutical giants are driving the market growth in Asia Pacific countries. Additionally, self-medication has become more prominent with easier access to OTC drugs via e-retailers and convenience stores. China, India, Japan, South Korea, Indonesia and other Southeast Asian countries offer immense untapped opportunities for OTC painkiller brands seeking to expand in Asia. Get More Insights On, Over The Counter Pain Medication Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
#Over The Counter Pain Medication Market Size#Over The Counter Pain Medication Market Demand#Over The Counter Pain Medication Market Trends#Over The Counter Pain Medication#Over The Counter Pain Medication Market
0 notes
Text
Priyanka Chigurupati – Leading Granules India Forward
Priyanka Chigurupati, a dynamic second-generation entrepreneur, is propelling her family’s pharmaceutical business, Granules India, into new heights. Starting her journey with Granules India as a marketing manager for a region-specific division, she quickly rose to oversee a new API facility and establish the US team for Granules Inc.
Early Life and Education
Priyanka’s path to the pharmaceutical industry was not initially clear. After earning a Bachelor of Science in Business Management from Case Western Reserve University in Cleveland, Ohio, she pursued her passion for fashion by obtaining an associate degree in Applied Science (Fashion Marketing) from Parsons, the New School of Design. She launched her fashion label, Chigurupati, designing Western and Indo-Western apparel for young women and retailing through e-commerce platforms, which was a novel approach at the time.
Entering the Family Business
In 2012, Priyanka was invited to join Granules India, the family-owned pharmaceutical company with operations in Hyderabad and the US. Granules India Ltd. is a vertically integrated pharmaceutical company focusing on R&D and multi-product delivery, including the manufacture of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Reflecting on her decision, Priyanka says, “I joined the family business of pharmaceuticals after pondering on what to do post my education in the US.”
Starting as a marketing manager, Priyanka embraced a collaborative approach, valuing collective decision-making over unilateral actions. This philosophy not only facilitated her learning but also instilled the confidence to influence organizational strategy, shifting the company’s focus towards manufacturing excellence.
Career Progression and Achievements
After a brief sabbatical, Priyanka returned to Granules India to manage a newly acquired API facility and subsequently relocated to the US. There, she drove the over-the-counter division as a project manager, later expanding her responsibilities to the prescription side of the business, which posed a new set of challenges due to the company’s limited R&D emphasis at the time. Her efforts culminated in her appointment as Executive Director of Granules Pharmaceuticals Inc. (GPI), where she oversaw the global business front-end, achieving 30+ abbreviated new drug application (ANDA) filings and their commercialization.
Currently, Priyanka leads the entire US generics business, which generates 50% of Granules’ overall revenues. She also manages the company’s portfolio and spearheads investor relations. Under her leadership, Granules has thrived in the competitive US generics market, maintaining a strong presence even as other Indian drug makers retreated from highly commoditized molecules like Paracetamol and Ibuprofen.
Expanding Horizons
Granules is actively expanding its operations, including setting up a new Multi-Unit Pellet System (MUPS) block in Telangana and an API block for medium to high-volume products. Internationally, the company is making inroads into Europe and enhancing its US market share. The company has seen significant growth, with consolidated revenue reaching Rs 2,598.65 crore in FY 19–20 and continued growth during the pandemic, driven by its essential services designation and commitment to uninterrupted medicine supply.
Personal Passions and Inspirations
Beyond her professional achievements, Priyanka is passionate about fitness and fashion, continuing to write and blog on these interests. Inspired by her marathon-running parents, who earned a Guinness World Record in 2010, she brings the same dedication and resilience to her leadership at Granules. Priyanka aims to consolidate and strengthen Granules’ position as a billion-dollar company, empowering her team to share in the organization’s vision with strong conviction and commitment.
Through her strategic vision and innovative leadership, Priyanka Chigurupati is not only honoring her family’s legacy but also ensuring Granules India’s sustained growth and success in the global pharmaceutical industry.
0 notes
Text
0 notes
Text
Ankylosing Spondylitis Market Projected to Show Strong Growth
The Latest research coverage on Ankylosing Spondylitis Market provides a detailed overview and accurate market size. The study is designed considering current and historical trends, market development and business strategies taken up by leaders and new industry players entering the market. Furthermore, study includes an in-depth analysis of global and regional markets along with country level market size breakdown to identify potential gaps and opportunities to better investigate market status, development activity, value and growth patterns. Access Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/35094-global-ankylosing-spondylitis-market
Major & Emerging Players in Ankylosing Spondylitis Market:- AbbVie Inc. (United States), Janssen Pharmaceuticals Inc. (Belgium), Pfizer Inc. (United States), Sandoz International GmbH (Germany), Amgen Inc. (United States), Protalix BioTherapeutics, Inc. (Israel), Reliance Life Sciences Pvt. Ltd. (India), Momenta Pharmaceuticals Inc. (United States), Celgene Corporation (United States), Regeneron Pharmaceuticals (United States), Merck & Co. Inc. (United States) The Ankylosing Spondylitis Market Study by AMA Research gives an essential tool and source to Industry stakeholders to figure out the market and other fundamental technicalities, covering growth, opportunities, competitive scenarios, and key trends in the Ankylosing Spondylitis market. Ankylosing spondylitis (AS) is a type of arthritis that mostly affects the back. It causes infection in the joints of the spine, leading to pain and stiffness. Ankylosing spondylitis affects people in diverse ways some people can almost forget they have the condition, while for others it can have a big effect on their quality of life and sometimes joints other than those in the spine can be affected too. Sometimes, other parts of the body may also be affected. Ankylosing spondylitis is a type of spondyloarthritis is a group of conditions that share many of the same symptoms.
The titled segments and sub-section of the market are illuminated below: by Application (Hospitals, Clinics, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral), Treatment Type (Nonsteroidal Anti-Inflammatory Drugs (Ibuprofen and Naproxen), Disease-Modifying Antirheumatic Drugs (Methotrexate), Biologics (Secukinumab, Certolizumab Pegol, and Infliximab)), Molecule Type (Small Molecules, Biologics, Biosimilars) Market Trends: Increasing Number of Treatment Seeking Population
Opportunities: Rising Research and Development Expenditure
Market Drivers: Increasing Prevalence of Ankylosing Spondylitis
Rising Awareness about Diagnostics and Treatments
Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/35094-global-ankylosing-spondylitis-market Some Point of Table of Content: Chapter One: Report Overview Chapter Two: Global Market Growth Trends Chapter Three: Value Chain of Ankylosing Spondylitis Market Chapter Four: Players Profiles Chapter Five: Global Ankylosing Spondylitis Market Analysis by Regions Chapter Six: North America Ankylosing Spondylitis Market Analysis by Countries Chapter Seven: Europe Ankylosing Spondylitis Market Analysis by Countries Chapter Eight: Asia-Pacific Ankylosing Spondylitis Market Analysis by Countries Chapter Nine: Middle East and Africa Ankylosing Spondylitis Market Analysis by Countries Chapter Ten: South America Ankylosing Spondylitis Market Analysis by Countries Chapter Eleven: Global Ankylosing Spondylitis Market Segment by Types Chapter Twelve: Global Ankylosing Spondylitis Market Segment by Applications What are the market factors that are explained in the Ankylosing Spondylitis Market report?
– Key Strategic Developments: Strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors.
– Key Market Features: Including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin.– Analytical Tools: The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market. Buy This Exclusive Research Here: https://www.advancemarketanalytics.com/buy-now?format=1&report=35094 Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market. Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 [email protected]
#Global Ankylosing Spondylitis Market#Ankylosing Spondylitis Market Demand#Ankylosing Spondylitis Market Trends#Ankylosing Spondylitis Market Analysis#Ankylosing Spondylitis Market Growth#Ankylosing Spondylitis Market Share#Ankylosing Spondylitis Market Forecast#Ankylosing Spondylitis Market Challenges
0 notes
Text
The Ibuprofen API Market was US$ 7.4 billion in 2022, and is projected to expand at a CAGR of 3.5% over the forecast period of 2023-2031.
0 notes
Text
Herpangina Treatment Market Growth Trajectory Through 2024-2033
The Herpangina Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033). Learn More On The Herpangina Treatment Market: https://www.thebusinessresearchcompany.com/report/herpangina-treatment-global-market-report According to The Business Research Company’s Herpangina Treatment Global Market Report 2024, The herpangina treatment market size has grown strongly in recent years. It will grow from $1.76 billion in 2023 to $1.88 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The herpangina treatment market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to emerging viral strains, increasing focus on pediatric health, international health regulations, technological innovations in diagnostics, healthcare access improvements.. The rise in prevalence of the herpangina is expected to propel the growth of the herpangina treatment market going forward. Herpangina is a viral illness that usually affects youngsters, creating painful sores or ulcers on the tonsils and back of the throat caused by coxsackievirus and enteroviruses. Herpangina therapy helps to reduce the severity of herpangina symptoms such as blisters, high fever, discomfort in the mouth or throat, drooling, and loss of appetite. Get A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample.aspx?id=10855&type=smp The herpangina treatment market covered in this report is segmented – 1) By Treatment: Topical Anesthetics, Ibuprofen Or Acetaminophen, Other Treatments 2) By Virus: Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus 3) By Symptoms: High Fever, Sore Throat, Blisters Or Ulcers In The Throat Mouth, Difficulty Swallowing, Loss Of Appetite, Neck Pain, Swollen Lymph Glands, and Headache 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users Development of treatments for herpangina diseases such as aphthous stomatitis is a key trend gaining popularity in the herpangina treatment market. Major companies operating in herpangina treatment are developing therapies for relieving pain for people suffering from recurrent mouth ulcers. For instance, in September 2022, Mucocort, a Sweden-based healthcare company that develops oral patches, signed a deal with Aurena Laboratories AB, a Sweden-based medical technology company, and created a unique self-absorbing pain relief patch. This unique patch treatment helps people suffering from recurrent mouth ulcers and aphthous stomatitis to relieve their pain and speeds up the natural healing process of the aphthous ulcer. The herpangina treatment market report table of contents includes: 1. Executive Summary 2. Market Characteristics 3. Market Trends And Strategies 4. Impact Of COVID-19 5. Market Size And Growth 6. Segmentation 7. Regional And Country Analysis . . . 27. Competitive Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected] Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
0 notes
Text
CANNABINOIDS , INJECTABLE STEROIDS , NEMBUTALS , ORAL STEROIDS , PAIN-KILLERS , PSYCHEDELICS , RESEARCH CHEMICALS , SEXUAL STIMULANTS
It seems like you're listing various types of substances, many of which are either controlled substances, prescription drugs, or potentially illegal. Here's a general overview: Cannabinoids: These are chemical compounds found in the cannabis plant. The most well-known is THC (delta-9-tetrahydrocannabinol), responsible for marijuana's psychoactive effects. Another is CBD (cannabidiol), which has therapeutic properties without the psychoactive effects. Cannabinoids are used medicinally in some areas and recreationally in others. Injectable Steroids: Steroids are a class of drugs that How to buy Belsomra in UK, USA include the corticosteroid drugs used to fight inflammation and anabolic steroids, which are related to male sex hormones and can help improve muscle growth and performance. Using them without a prescription is illegal and can cause severe side effects. Nembutals (Pentobarbital): This is a barbiturate drug. It has historically been used as a sleeping pill, but its use for this purpose has largely been replaced due to overdose concerns. It's currently used in some jurisdictions for physician-assisted suicide. Oral Steroids: Similar to injectable steroids, these are taken by mouth. They can be corticosteroids or anabolic steroids. Pain-killers: This is a broad category that includes over-the-counter analgesics like acetaminophen or ibuprofen, as well as prescription opioids like oxycodone or morphine. Opioids, in particular, have been linked to addiction and the ongoing opioid crisis. Psychedelics: These are substances that alter perception, mood, and various cognitive processes. Examples include LSD, psilocybin (magic mushrooms), and DMT. Research Chemicals: This term often refers to novel or designer drugs that have been synthesized to mimic the effects of established illegal drugs. Their effects on humans are often not well-understood since they haven't been tested. Sexual Enhancers: These might refer to drugs like Viagra or Cialis, which are used to treat erectile dysfunction. They can also include other substances or products marketed to improve sexual performance or pleasure. Stimulants: Drugs that increase activity in the central nervous system. This includes caffeine, nicotine, and amphetamines. They can boost alertness, attention, and energy. It's essential to approach the use or purchase of any of these substances with caution. Many are regulated, controlled, or illegal in many jurisdictions, and misuse can lead to severe health complications or legal consequences. Always consult with a medical professional before starting any new drug or substance.
0 notes
Text
Menstrual Cramps Treatment: High Growth Owing to Adoption of Non-Invasive Treatment Options
Menstrual cramps or dysmenorrhoea commonly known as period pain is one of the most common gynecological problems faced by women worldwide. It refers to lower abdominal pain which occurs just before or during menstruation. Various non-invasive treatment options are available in the market for effective relief from menstrual cramps including oral contraceptives, NSAIDs, homeopathy, acupuncture etc. Oral contraceptives work by preventing ovulation and thinning the uterine lining which reduces menstrual cramps. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen help reduce pain and inflammation by blocking the production of prostaglandins which are substances in the body that can cause cramping. The global Menstrual Cramps Treatment Market is estimated to be valued at US$ 652.3 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The high adoption of non-invasive treatment alternatives for menstrual cramps presents a major market opportunity. Non-invasive options are preferred over invasive methods as they are generally safer, more cost-effective and have minimal side effects. With growing awareness about non-surgical treatments and advantages of NSAIDs and oral hormonal contraceptives, their demand and adoption is increasing considerably. This rising preference for non-invasive options among women is expected to fuel robust market growth over the forecast period. Porter's Analysis Threat of new entrants: The threat is relatively low due to high capital investment required for R&D and production facilities along with established distribution channels and brand loyalty. Bargaining power of buyers: The bargaining power of buyers is moderate since there are numerous options available for menstrual cramps treatment with established brands. However, shifting preference towards herbal alternative therapy is increasing buyer power. SWOT Analysis Strength: Wide range of prescription drugs and medical devices for menstrual pain relief with clinically proven efficacy. Established global distribution and promotion networks. Weakness: Growing side effects related safety concerns of NSAIDs limiting their long term use. High promotion expenses incurred by companies to create product awareness. Opportunity: Emerging economies with large reproductive age population present huge market potential. Rising focus on herbal and alternative therapies catering to shift towards holistic healthcare. Threats: Stringent regulatory approval process for new therapies delaying product launches. Intense price competition from generic drug manufacturers. Key Takeaways The global Menstrual Cramps Treatment Market is expected to witness high growth over the forecast period of 2023 to 2030. Regional analysis: Asia Pacific region dominates the global market and is expected to grow at the fastest CAGR during the forecast period due to rising disposable income, growing awareness about menstrual health, and increasing availability of treatment options. China represents the largest market in the Asia Pacific region followed by India. Key players: Key players operating in the Menstrual Cramps Treatment market are Stryker Corporation, SATELEC (Actongroup), Surgiform Innovative Surgical Products, Allergan (Abbvie) Luminera, Implantech, Koken, ANTHONY PRODUCTS INC., NOUVAG, Sihuan Pharmaceutical Holdings Group Ltd., and Other. Key players are mainly focused on new product launches and acquisitions to strengthen their market position.
0 notes
Text
CANNABINOIDS , INJECTABLE STEROIDS , NEMBUTALS , ORAL STEROIDS , PAIN-KILLERS , PSYCHEDELICS , RESEARCH CHEMICALS , SEXUAL STIMULANTS
It seems like you're Dilaudid in UK, USA listing various types of substances, many of which are either controlled substances, prescription drugs, or potentially illegal. Here's a general overview: Cannabinoids: These are chemical compounds found in the cannabis plant. The most well-known is THC (delta-9-tetrahydrocannabinol), responsible for marijuana's psychoactive effects. Another is CBD (cannabidiol), which has therapeutic properties without the psychoactive effects. Cannabinoids are used medicinally in some areas and recreationally in others. Injectable Steroids: Steroids are a class of drugs that include the corticosteroid drugs used to fight inflammation and anabolic steroids, which are related to male sex hormones and can help improve muscle growth and performance. Using them without a prescription is illegal and can cause severe side effects. Nembutals (Pentobarbital): This is a barbiturate drug. It has historically been used as a sleeping pill, but its use for this purpose has largely been replaced due to overdose concerns. It's currently used in some jurisdictions for physician-assisted suicide. Oral Steroids: Similar to injectable steroids, these are taken by mouth. They can be corticosteroids or anabolic steroids. Pain-killers: This is a broad category that includes over-the-counter analgesics like acetaminophen or ibuprofen, as well as prescription opioids like oxycodone or morphine. Opioids, in particular, have been linked to addiction and the ongoing opioid crisis. Psychedelics: These are substances that alter perception, mood, and various cognitive processes. Examples include LSD, psilocybin (magic mushrooms), and DMT. Research Chemicals: This term often refers to novel or designer drugs that have been synthesized to mimic the effects of established illegal drugs. Their effects on humans are often not well-understood since they haven't been tested. Sexual Enhancers: These might refer to drugs like Viagra or Cialis, which are used to treat erectile dysfunction. They can also include other substances or products marketed to improve sexual performance or pleasure. Stimulants: Drugs that increase activity in the central nervous system. This includes caffeine, nicotine, and amphetamines. They can boost alertness, attention, and energy. It's essential to approach the use or purchase of any of these substances with caution. Many are regulated, controlled, or illegal in many jurisdictions, and misuse can lead to severe health complications or legal consequences. Always consult with a medical professional before starting any new drug or substance.
0 notes
Text
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast to 2027
The prevalence of chronic pain imposes a significant health and economic burden due to reduced productivity and treatment expenses. Non-steroidal anti-inflammatory drugs (NSAIDs) are the primary choice for alleviating pain and inflammation. The increasing incidence of conditions like rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, and migraines is driving the demand for these medications. They have become the most widely prescribed drugs worldwide, with approximately 84 million NSAID prescriptions issued annually in the U.S., as stated in a press release by Endo International plc.
Here are some key points about the NSAIDs market as of 2021:
Market Size and Growth: The global NSAIDs market was valued in the billions of US dollars. The market was expected to continue growing, driven by factors such as an aging population, an increasing incidence of chronic diseases, and a rising awareness of the benefits of NSAIDs.
Types of NSAIDs: The market includes various types of NSAIDs, such as ibuprofen, naproxen, aspirin, diclofenac, and others. Each type has specific indications and varying levels of market share.
Indications: NSAIDs are used primarily to manage pain, inflammation, and fever. They find applications in various medical conditions like arthritis, headaches, menstrual cramps, and musculoskeletal injuries.
Prescription vs. Over-the-Counter (OTC): Some NSAIDs are available over-the-counter, while others require a prescription. OTC NSAIDs are widely used for mild to moderate pain relief, while prescription NSAIDs are often used for more severe conditions.
Distribution Channels: NSAIDs are distributed through various channels, including hospitals, pharmacies, online retail, and others. The choice of channel depends on factors like the type of NSAID, the severity of the condition, and regional preferences.
Regional Trends: The market for NSAIDs may vary significantly by region. Factors such as healthcare infrastructure, regulatory policies, and cultural preferences can influence market dynamics.
Competitive Landscape: The NSAIDs industry is competitive, with several pharmaceutical companies manufacturing and marketing these drugs. Some of the major players in the market include Pfizer, Bayer, Novartis, Johnson & Johnson, and GlaxoSmithKline, among others.
0 notes
Text
Herpangina Treatment Market Share, Size, Research, CAGR, and Growth - Forecast 2030
Global Herpangina Treatment Market, By Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus), Symptoms (High Fever, Sore Throat, Blisters Or Ulcers In The Throat And Mouth, Difficulty Swallowing, Loss Of Appetite, Headache, Neck Pain, Swollen Lymph Glands), Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
In the consistent Herpangina Treatment market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Herpangina Treatment industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Herpangina Treatment market report brings precise and exact market research information that drives business into the right direction.
Key Players
Major companies operating in the closed system transfer devices market are ICU Medical, Inc., BD, B. Braun Medical Inc., EQUASHIELD, YUKON MEDICAL, Simplivia, Caragen Ltd., Vygon, Epic Medical and others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Browse More Info @ https://www.databridgemarketresearch.com/reports/global-herpangina-treatment-market
The research studies entailed in the winning Herpangina Treatment market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.
Key questions answered in the report:
Which product segment will grab a lion’s share?
Which regional market will emerge as a frontrunner in coming years?
Which application segment will grow at a robust rate?
Report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios of the top players in the Herpangina Treatment Market.
Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.
Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
Table Of Content
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Global Market
Part 04: Global Market Size
Part 05: Global Market Segmentation By Product
Part 06: Five Forces Analysis
More Reports:
Diuretic Drugs Market
Patient Engagement Technology Market
Healthcare Business Intelligence Market
Chinese Hamster Ovary cells (CHO) Market
Anti-cancer Drug Market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
0 notes